Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Total Valuation
Addex Therapeutics has a market cap or net worth of $11.25M. The enterprise value is .
Market Cap$11.25M
Enterprise Value
Share Statistics
Addex Therapeutics has 1.54M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.54M
Owned by Insiders
Owned by Instutions0.07%
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -9.22 and return on invested capital (ROIC) is -508.33%.
Return on Equity (ROE)-921.57%
Return on Assets (ROA)-227.41%
Return on Invested Capital (ROIC)-508.33%
Return on Capital Employed (ROCE)-587.97%
Revenue Per Employee$24,238.043
Profits Per Employee$234,986.304
Employee Count23
Asset Turnover0.35
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is -0.30. Addex Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.30
PS Ratio1.95
PB Ratio2.75
Price to Fair Value2.75
Price to FCF-0.39
Price to Operating Cash Flow-0.39
PEG Ratio<0.01
Income Statement
In the last 12 months, Addex Therapeutics had revenue of $557.48K and earned $5.40M in profits. Earnings per share was $0.05.
Revenue$557.48K
Gross Profit-$988.78K
Operating Income-$4.99M
Pretax Income-$6.58M
Net Income$5.40M
EBITDA-6.37M
Earnings Per Share (EPS)0.05
Cash Flow
In the last 12 months, operating cash flow was -$5.97M and capital expenditures -$2.48K, giving a free cash flow of -$5.97M billion.
Operating Cash Flow-$5.97M
Free Cash Flow-$5.97M
Free Cash Flow per Share-$3.89
Dividends & Yields
Addex Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-2.12%
Earnings Yield-335.14%
Stock Price Statistics
Beta-0.11
52-Week Price Change-71.84%
50-Day Moving Average7.55
200-Day Moving Average8.50
Relative Strength Index (RSI)45.37
Average Volume (3m)8.80K
Important Dates
Addex Therapeutics upcoming earnings date is Apr 21, 2025, TBA.
Last Earnings DateNov 22, 2024
Next Earnings DateApr 21, 2025
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 1.46, with Debt / Equity ratio of 0.30
Current Ratio1.46
Quick Ratio1.46
Debt to Market Cap0.00
Net Debt to EBITDA0.34
Interest Coverage Ratio-475.83
Taxes
In the past 12 months, Addex Therapeutics has paid $3.10M in taxes.
Income Tax$3.10M
Effective Tax Rate0.00%
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -36.61, with an EV/FCF ratio of -46.81.
EV to Sales232.15
EV to EBITDA-36.61
EV to Free Cash Flow-46.81
EV to Operating Cash Flow-46.85
Balance Sheet
Addex Therapeutics has $3.35M in cash and marketable securities with $43.77K in debt, giving a net cash position of -$3.31M billion.
Cash & Marketable Securities$3.35M
Total Debt$43.77K
Net Cash-$3.31M
Net Cash Per Share-$2.15
Tangible Book Value Per Share$0.02
Margins
Gross margin is -329.99%, with operating margin of -637.42%, and net profit margin of -654.47%.
Gross Margin-329.99%
Operating Margin-637.42%
Pretax Margin-654.47%
Net Profit Margin-654.47%
EBITDA Margin-634.16%
EBIT Margin-653.13%
Analyst Forecast
The average price target for Addex Therapeutics is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-70.05%
EPS Growth Forecast